Assessment of Fetal Pancreatic Size and Maternal Serum Biomarkers in GDM

NCT05392231 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 109

Last updated 2022-06-01

No results posted yet for this study

Summary

The investigators aimed to determine the predictive values of fetal pancreas size and maternal serum biomarkers glycated albumin (GA) and insulin-regulated aminopeptidase (IRAP) for gestational diabetes mellitus (GDM).

Conditions

  • Gestational Diabetes

Sponsors & Collaborators

  • Haseki Training and Research Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-10
Primary Completion
2022-04-30
Completion
2022-05-10

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05392231 on ClinicalTrials.gov